Results 91 to 100 of about 1,143 (109)

Donanemab in Early Alzheimer’s Disease

New England Journal of Medicine, 2021
Alette M Wessels, Sergey Shcherbinin, John R Sims   +2 more
exaly  

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

Nature Reviews Drug Discovery, 2010
Harald Hampel, Jessen Frank, Stefan J Teipel   +2 more
exaly  

Drug repositioning for Alzheimer's disease

Nature Reviews Drug Discovery, 2012
Anne Corbett, James Pickett, Alistair Burns   +2 more
exaly  

Alzheimer's disease: strategies for disease modification

Nature Reviews Drug Discovery, 2010
Martin Citron, Citron Martin
exaly  

Alzheimer's Disease

New England Journal of Medicine, 2010
Frank M Laferla, Laferla Frank M
exaly  

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

New England Journal of Medicine, 2012
Randall J Bateman, Alison Goate, Nick C Fox   +2 more
exaly  

Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease

Nature Reviews Drug Discovery, 2013
Paul S Aisen, Bruno Vellas, Harald Hampel   +2 more
exaly  

A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease

Cell, 2017
Hadas Keren-Shaul, Amit Spinrad, Assaf Weiner   +2 more
exaly  

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

Nature, 2012
Thorlakur Jonsson, Jasvinder K Atwal, Jon Snaedal   +2 more
exaly  

Alzheimer's disease

Nature Reviews Disease Primers, 2015
Colin L Masters, Randall J Bateman, KAJ Blennow   +2 more
exaly